Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Laureate Pharma Announces New Development and Manufacturing Agreement to Produce AVEO Pharmaceuticals’ Antibody Therapeutic

October 27, 2010 By Bio-Medicine.Org

PRINCETON, N.J., Oct. 27 /PRNewswire/ — Laureate Pharma, Inc.,
a full-service contract development and manufacturing organization,
announced today that they have entered into a development and
manufacturing agreement to produce AV-203, AVEO Pharmaceutical’s
(Cambridge, MA) novel monoclonal antibody targeted against ErbB3.
 Laureate’s services will include process development, protein
production, purification and aseptic filling of AP-203 for AVEO.
 The project is presently underway and Laureate expects to
supply AVEO with clinical product in the second quarter of 2011.
 Terms of the manufacturing agreement were not disclosed.

“AVEO has a very impressive pipeline of monoclonal
antibody-based products for treatment of cancer and we are pleased
to work with them on this exciting antibody product,” said Steve
Johnson, Vice President, Business Development, of Laureate Pharma.
 “We look forward to a productive and successful relationship
with AVEO to provide clinical supply of their monoclonal
antibodies.”

AV-203 is an ErbB3 (HER3)-targeted antibody. ErbB3 belongs to a
family of four proteins that also includes the epidermal growth
factor receptor (EGFR) and the HER2 receptor. Both EGFR and HER2
have been implicated in promoting the growth of significant numbers
of tumors, particularly in breast and lung cancers. Drugs blocking
the activity of EGFR have demonstrated clinical benefit in lung,
colon and head and neck cancers, while drugs targeting HER2 show
clinical benefit in the treatment of HER2 over-expressing breast
cancers. ErbB3 is significantly over-expressed in many human
breast, ovarian, prostate, colorectal, pancreatic, gastric, and
head and neck cancers, which generally correlates with poor
prognosis.

About Laureate Pharma

Laureate Pharma is a full-service biopharmaceutical contract
development and manufacturing organization. Laureate’s scientists
are expert in process development and cGMP production of

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech